Concepts (87)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Genital Neoplasms, Female | 3 | 2021 | 45 | 1.600 |
Why?
|
| Oncologists | 2 | 2021 | 29 | 1.430 |
Why?
|
| Intestinal Obstruction | 2 | 2021 | 97 | 1.270 |
Why?
|
| Uterine Cervical Neoplasms | 3 | 2024 | 217 | 1.130 |
Why?
|
| Uterine Neoplasms | 2 | 2019 | 117 | 1.070 |
Why?
|
| Ovarian Neoplasms | 3 | 2019 | 412 | 1.060 |
Why?
|
| Surgical Procedures, Operative | 1 | 2022 | 182 | 0.730 |
Why?
|
| Hospice and Palliative Care Nursing | 1 | 2021 | 18 | 0.730 |
Why?
|
| Informed Consent | 1 | 2022 | 340 | 0.680 |
Why?
|
| Cancer Survivors | 2 | 2018 | 169 | 0.610 |
Why?
|
| Pregnancy Tests | 1 | 2016 | 2 | 0.540 |
Why?
|
| Gestational Trophoblastic Disease | 1 | 2016 | 7 | 0.530 |
Why?
|
| Hydatidiform Mole | 1 | 2016 | 19 | 0.530 |
Why?
|
| Chorionic Gonadotropin | 1 | 2016 | 83 | 0.520 |
Why?
|
| Early Detection of Cancer | 2 | 2024 | 338 | 0.520 |
Why?
|
| Hemoperitoneum | 1 | 2015 | 8 | 0.510 |
Why?
|
| Papillomavirus Infections | 2 | 2024 | 258 | 0.510 |
Why?
|
| Postoperative Hemorrhage | 1 | 2015 | 87 | 0.480 |
Why?
|
| Biomarkers, Tumor | 2 | 2021 | 1414 | 0.420 |
Why?
|
| Phlebotomy | 1 | 2012 | 17 | 0.420 |
Why?
|
| Palliative Care | 3 | 2021 | 429 | 0.410 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2012 | 20 | 0.410 |
Why?
|
| Developed Countries | 1 | 2012 | 34 | 0.410 |
Why?
|
| Cesarean Section | 1 | 2015 | 376 | 0.400 |
Why?
|
| Developing Countries | 1 | 2012 | 270 | 0.360 |
Why?
|
| Ultrasonography | 1 | 2015 | 945 | 0.360 |
Why?
|
| Cystadenocarcinoma, Serous | 2 | 2018 | 47 | 0.300 |
Why?
|
| Female | 12 | 2024 | 64574 | 0.230 |
Why?
|
| Feasibility Studies | 2 | 2016 | 745 | 0.210 |
Why?
|
| HIV Seropositivity | 1 | 2023 | 116 | 0.200 |
Why?
|
| Humans | 15 | 2024 | 121798 | 0.200 |
Why?
|
| Herpesviridae Infections | 1 | 2023 | 142 | 0.200 |
Why?
|
| Chicago | 1 | 2020 | 20 | 0.180 |
Why?
|
| Social Environment | 1 | 2018 | 118 | 0.150 |
Why?
|
| Violence | 1 | 2018 | 113 | 0.150 |
Why?
|
| Pain | 1 | 2021 | 440 | 0.150 |
Why?
|
| Physician-Patient Relations | 1 | 2021 | 423 | 0.150 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2017 | 36 | 0.150 |
Why?
|
| Communication | 1 | 2021 | 505 | 0.140 |
Why?
|
| Emergency Service, Hospital | 1 | 2024 | 1064 | 0.140 |
Why?
|
| Neoplasm Grading | 1 | 2017 | 263 | 0.140 |
Why?
|
| Referral and Consultation | 1 | 2020 | 524 | 0.130 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2019 | 1103 | 0.130 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 864 | 0.130 |
Why?
|
| Adult | 5 | 2024 | 28548 | 0.130 |
Why?
|
| Wounds and Injuries | 1 | 2018 | 348 | 0.120 |
Why?
|
| Health Services Accessibility | 1 | 2018 | 585 | 0.110 |
Why?
|
| Pregnancy | 2 | 2016 | 7045 | 0.110 |
Why?
|
| Acetic Acid | 1 | 2012 | 18 | 0.100 |
Why?
|
| Human Papillomavirus DNA Tests | 1 | 2012 | 6 | 0.100 |
Why?
|
| Hyperbilirubinemia | 1 | 2012 | 40 | 0.100 |
Why?
|
| Vaginal Smears | 1 | 2012 | 47 | 0.100 |
Why?
|
| Unnecessary Procedures | 1 | 2012 | 55 | 0.100 |
Why?
|
| Antineoplastic Agents | 1 | 2021 | 1672 | 0.100 |
Why?
|
| Retrospective Studies | 3 | 2021 | 15794 | 0.100 |
Why?
|
| Bilirubin | 1 | 2012 | 128 | 0.100 |
Why?
|
| Triage | 1 | 2012 | 140 | 0.100 |
Why?
|
| Papillomavirus Vaccines | 1 | 2012 | 89 | 0.090 |
Why?
|
| Aged, 80 and over | 2 | 2019 | 6275 | 0.090 |
Why?
|
| Middle Aged | 5 | 2024 | 25515 | 0.090 |
Why?
|
| Cost-Benefit Analysis | 1 | 2012 | 491 | 0.090 |
Why?
|
| Neoplasms | 1 | 2023 | 2697 | 0.080 |
Why?
|
| Aged | 3 | 2021 | 18732 | 0.070 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 4952 | 0.070 |
Why?
|
| Prospective Studies | 1 | 2015 | 5960 | 0.060 |
Why?
|
| Hospitals, Urban | 1 | 2024 | 97 | 0.060 |
Why?
|
| Specimen Handling | 1 | 2024 | 138 | 0.060 |
Why?
|
| Treatment Outcome | 1 | 2019 | 12003 | 0.050 |
Why?
|
| Self Care | 1 | 2024 | 203 | 0.050 |
Why?
|
| Young Adult | 1 | 2016 | 8675 | 0.050 |
Why?
|
| HIV Infections | 1 | 2012 | 1842 | 0.050 |
Why?
|
| Patient Care Planning | 1 | 2021 | 122 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2024 | 412 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2024 | 1365 | 0.040 |
Why?
|
| Neutropenia | 1 | 2021 | 201 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2012 | 8009 | 0.040 |
Why?
|
| Thrombocytopenia | 1 | 2021 | 228 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2021 | 793 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2021 | 353 | 0.040 |
Why?
|
| Mass Screening | 1 | 2024 | 779 | 0.040 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2018 | 30 | 0.040 |
Why?
|
| Precision Medicine | 1 | 2021 | 306 | 0.040 |
Why?
|
| Texas | 1 | 2024 | 3431 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2018 | 847 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2021 | 988 | 0.030 |
Why?
|
| Male | 1 | 2015 | 59250 | 0.020 |
Why?
|
| Mutation | 1 | 2021 | 5773 | 0.020 |
Why?
|